Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

ID DOID:80638
Name B-cell acute lymphoblastic leukemia
Definition An acute lymphocytic leukemia characterized by too many B-cell lymphoblasts (immature white blood cells) in the bone marrow and blood.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer hematologic cancer leukemia lymphoid leukemia acute leukemia acute lymphoblastic leukemia B-cell acute lymphoblastic leukemia

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FLT3 exon 14 ins CD19/CD22 CAR T cells B-cell acute lymphoblastic leukemia predicted - sensitive detail...
SF3B1 K700E Indisulam B-cell acute lymphoblastic leukemia sensitive detail...
SF3B1 K666N Indisulam B-cell acute lymphoblastic leukemia sensitive detail...
SF3B1 H662Q Indisulam B-cell acute lymphoblastic leukemia sensitive detail...
SF3B1 H662Q E7820 B-cell acute lymphoblastic leukemia sensitive detail...
SF3B1 K666N E7820 B-cell acute lymphoblastic leukemia sensitive detail...
SF3B1 K700E E7820 B-cell acute lymphoblastic leukemia sensitive detail...
Unknown unknown Loncastuximab tesirine B-cell acute lymphoblastic leukemia not applicable detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00450944 Phase I Combotox Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia Recruiting
NCT01087294 Phase I Anti-CD19 CAR T cells Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell Transplantation Recruiting
NCT01853631 Phase I Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine Activated T-Cells Expressing 2nd or 3rd Generation CD19-Specific CAR, Advanced B-Cell NHL, ALL, and CLL (SAGAN) (SAGAN) Recruiting
NCT02143414 Phase II Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Dasatinib + Prednisone Blinatumomab + Dasatinib Blinatumomab Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patients With Acute Lymphoblastic Leukemia Recruiting
NCT02311998 Phase Ib/II Bosutinib + Inotuzumab ozogamicin Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML Recruiting
NCT02315612 Phase I Anti-CD22 CAR T cells Anti-CD22 Chimeric Receptor T Cells in Pediatric and Young Adults With Recurrent or Refractory CD22-expressing B Cell Malignancies Recruiting
NCT02420717 Phase II Ruxolitinib Cyclophosphamide + Dexamethasone + Doxorubicin + Vincristine Sulfate Dasatinib Mercaptopurine + Methotrexate + Prednisone + Vincristine Sulfate Cytarabine + Leucovorin + Methotrexate Ruxolitinib Phosphate or Dasatinib With Chemotherapy in Treating Patients With Relapsed or Refractory Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia Active, not recruiting
NCT02435849 Phase II Tisagenlecleucel Determine Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell ALL and High Risk B-cell ALL at First Relapse. Determine Feasibility and Safety of CTL019 Therapy in Pediatric Patients With High Risk B-cell ALL That Relapsed < 6 Months Post All-HSCT. (ELIANA) Active, not recruiting
NCT02535806 Phase II Vincristine Sulfate Bortezomib Pegaspargase Methotrexate Cytarabine Mitoxantrone Prednisone Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults Terminated
NCT02650414 Phase I Anti-CD22 CAR T cells CD22 Redirected Autologous T Cells for ALL Recruiting
NCT02730312 Phase I XmAb14045 PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies Recruiting
NCT02828358 Phase II Cytarabine + Hydrocortisone + Leucovorin + Mercaptopurine + Pegaspargase Cyclophosphamide + Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Cytarabine + Hydrocortisone + Mercaptopurine + Methotrexate Azacitidine Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Pegaspargase + Thioguanine + Vincristine sulfate liposome Cytarabine + Daunorubicin + Dexamethasone + Hydrocortisone + Methotrexate + Pegaspargase + Prednisolone + Vincristine Sulfate Mercaptopurine + Methotrexate Cyclophosphamide + Cytarabine + Thioguanine Azacitidine and Combination Chemotherapy in Treating Infants With Acute Lymphoblastic Leukemia and KMT2A Gene Rearrangement Active, not recruiting
NCT03016377 Phase Ib/II Anti-CD19 CAR T cells Cyclophosphamide + Fludarabine Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL Recruiting
NCT03123939 Phase III Tisagenlecleucel Phase III B in Acute Lymphoblastic Leukemia Active, not recruiting
NCT03233854 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/CD22 Chimeric Antigen Receptor(CAR) T Cells in Adults With Recurrent/Refractory B Cell Malignancies Suspended
NCT03441061 Phase II Inotuzumab ozogamicin Inotuzumab Ozogamicin in Treating Patients With B-cell Acute Lymphocytic Leukemia With Positive Minimal Residual Disease Recruiting
NCT03448393 Phase I Cyclophosphamide + Fludarabine CD19/CD22 CAR T cells CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory CD19/CD22-expressing B Cell Malignancies Recruiting
NCT03620058 Phase I CART22-65s cells + huCART19 CART22-65s cells CART22 Alone or in Combination With huCART19 for ALL Recruiting
NCT03677596 FDA approved Inotuzumab ozogamicin A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients Recruiting
NCT03743246 Phase Ib/II Cyclophosphamide + Fludarabine + JCAR017 A Study to Evaluate the Safety and Efficacy of JCAR017 in Pediatric Subjects With Relapsed/Refractory (r/r) B-cell Acute Lymphoblastic Leukemia (B-ALL) and B-cell Non-Hodgkin Lymphoma (B-NHL) Recruiting
NCT03792633 Phase II huCART19 Study of huCART19 for Very High-Risk (VHR) Subsets of Pediatric B-ALL Recruiting
NCT03833180 Phase I VLS-101 A Phase 1 Dose-Escalation and Cohort-Expansion of VLS-101 in Hematologic Malignancies Recruiting
NCT03876769 Phase II Tisagenlecleucel Study of Efficacy and Safety of Tisagenlecleucel in HR B-ALL EOC MRD Positive Patients (CASSIOPEIA) Recruiting
NCT04029038 Phase Ib/II CD19/CD22 CAR T cells Modified Immune Cells (CD19-CD22 CAR T Cells) in Treating Patients With Recurrent or Refractory CD19 Positive, CD22 Positive Leukemia or Lymphoma Not yet recruiting
NCT04029688 Phase Ib/II Idasanutlin + Venetoclax Cyclophosphamide + Idasanutlin + Topotecan Cytarabine + Fludarabine + Idasanutlin Cytarabine + Hydrocortisone + Methotrexate Cytarabine Methotrexate Idasanutlin Cyclophosphamide + Idasanutlin A Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of Idasanutlin in Combination With Either Chemotherapy or Venetoclax in the Treatment of Pediatric and Young Adult Participants With Relapsed/Refractory Acute Leukemias or Solid Tumors Recruiting
NCT04049383 Phase I Anti-CD19-CD20 CAR T cells CAR-20/19-T Cells in Pediatric Patients With Relapsed/Refractory B Cell ALL (CAR-20/19-T) Not yet recruiting
NCT04094311 Phase III Tisagenlecleucel Study of Out of Specification for Tisagenlecleucel Recruiting
NCT04214886 Phase I CD19-CD34 CAR transduced T cells + Cyclophosphamide + Fludarabine CD19 Chimeric Antigen Receptor (CAR) T Cells for Adults With Recurrent or Refractory B Cell Malignancies Recruiting
NCT04509700 Phase II Parsaclisib Itacitinib + Parsaclisib Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) Recruiting
NCT04512716 Phase I Anti-CD19CAR-CD28-CD3zeta-EGFRt T cells + Iomab-B Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia or Diffuse Large B-Cell Lymphoma Not yet recruiting